Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
4/7/2009 8:58:39 AM
More...
|
DOR BioPharma, Inc. (DORB) Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
2/12/2009 6:58:45 AM
More...
|
Malaria: New Treatment is Upcoming Developed by the Italian Pharmaceutical Company sigma-tau New Data Confirm the Absence of Side Effects and the Benefit of the Simpler Treatment Schedule
1/16/2009 10:29:16 AM
More...
|
Pfizer Inc. (PFE) (JOBS) and Sigma-Tau Pharmaceuticals Announce an Agreement to Market a Potential New Treatment for Malaria in Africa
12/9/2008 7:12:16 AM
More...
|
DOR BioPharma, Inc. (DORB) Receives $1.5 Million From Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec(R) Strategic Alliance
12/1/2008 8:43:09 AM
More...
|
Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Americans
7/9/2008 12:37:08 PM
More...
|
Sigma-Tau Pharmaceuticals Release: FDA Approves Carnitor(R) SF (Levocarnitine) Sugar-Free Oral Solution For Patients With Carnitine Deficiency
6/22/2007 12:34:08 PM
More...
|
SciClone Pharmaceuticals, Inc. (SCLN) and Sigma-Tau Pharmaceuticals Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
6/4/2007 10:40:00 AM
More...
|
DOR BioPharma, Inc. (DORB) Receives $3 Million From Sigma-Tau Pharmaceuticals For Exclusive Right To Negotiate orBec(R) Strategic Alliance
1/4/2007 1:52:48 PM
More...
|
SciClone Pharmaceuticals, Inc. (SCLN) And Sigma-Tau Pharmaceuticals Complete Enrollment In Phase 3 Triple Therapy Hepatitis C Clinical Trial
12/28/2006 10:49:11 AM
More...
|
|